Terazosin and Tamsulosin Combination Therapy for BPH

Pharmacological Classification and Mechanism

Both terazosin and tamsulosin are alpha-1 adrenergic receptor antagonists that work by inhibiting alpha1-adrenergic-mediated contraction of prostatic smooth muscle, thereby relieving bladder outlet obstruction 1
Using both agents simultaneously would be pharmacologically redundant and does not follow evidence-based practice 1, 2

The American Urological Association (AUA) guidelines indicate that alfuzosin, doxazosin, tamsulosin, and terazosin are all appropriate treatment options for patients with lower urinary tract symptoms (LUTS) secondary to BPH 1
These alpha-blockers have been shown to be similarly effective in relieving symptoms, producing on average a 4-to-6 point improvement in the AUA Symptom Index 2
Clinical data supports the efficacy of titrating patients to 0.8 mg of tamsulosin (from 0.4 mg) or 10 mg of terazosin, but not using both medications simultaneously 1

The primary adverse events reported with alpha-blocker therapy include orthostatic hypotension, dizziness, tiredness (asthenia), ejaculatory problems, and nasal congestion 2
Tamsulosin appears to have a lower probability of orthostatic hypotension but a higher probability of ejaculatory dysfunction compared to terazosin 1

Never combine two medications from the same pharmacological class (such as two alpha-blockers) as this increases the risk of adverse effects without providing additional therapeutic benefit 1, 2
In patients with hypertension requiring alpha-blocker therapy for BPH, be aware that alpha-blockers used for BPH management may not provide optimal blood pressure control 2